Health Condition 1: null- Rheumatoid Arthritis (Amavata)
Conditions
Interventions
Intervention1: 1. Punarnava Guggulu (Bhaishajya Ratnavali, Amavata Chikitsa,29.152-154)
2.Rasna saptaka Kashaya (Chakradatta, Amavata Chikitsa, Sloka 8): 1.Punarnava Guggulu (Bhaishajya Ratnaval
Dose:
Sponsors
CENTRAL COUNCIL FOR RESEARCH IN AYURVDEDIC SCIENCES
Eligibility
Inclusion criteria
Inclusion criteria: 1). Patients of either sex with age between 20 and 60 years 2). Presence of any four out of the following seven criteria (according to 1987, revised criteria of American College of Rheumatology) a. Morning stiffness: Stiffness in and around joints lasting one hour before maximal improvement (More than 6 weekâ??s duration). b. Arthritis of three or more joints, at least three joint area, observed by Physician, having pain with soft tissue swelling or joint effusion, not just bony over growth, (more than 6 weeks duration). c. Arthritis of hand joints, at least 1 area in wrist and hand is swollen (more than 6 weeks duration). d. Symmetric arthritis (more than 6 weekâ??s duration). e. Presence of rheumatoid Nodules f. Serum rheumatoid factor- positive g. Typical radiographic changes of arthritis on PA view of hand & wrist radiograph that must include erosions or unequivocal bony decalcification, localized in or adjacent to involved joints. 3).Patients willing and able to participate in the study for 14 weeks.
Exclusion criteria
Exclusion criteria: 1. Patients who have developed complications of Rheumatoid Arthritis e.g. deformity of joints / bones, pleura-pericardial disease, or else. 2. Patients who are unable to walk without support and / or confined to wheel chair. 3. Patients with structural deformity as the complication of RA. 4. Patients with poorly controlled Hypertension ( >160/100 mm of Hg) 5. Patients with poorly controlled Diabetes Mellitus ({B.S. (F) >126 mg/dl and /or B.S.(2 hr. PP) >200 mg/dl}. 6. Patients diagnosed with other arthritis like gouty arthritis, tuberculous arthritis etc. 7. Patients on prolonged ( > 6 weeks) medication with corticosteoids, antidepressants, anticholin- ergics, etc. or any other drugs that may have an influence on the outcome of the study. 8. Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. 9. Symptomatic patients with clinical evidence of Heart failure. 10.Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg /dL), Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]), or any other condition that may jeopardize the study. 11. Alcoholics and/or drug abusers. 12. H/o hypersensitivity to any of the trial drugs or their ingredients. 13. Pregnant / lactating woman. 14. Patients who have completed participation in any other clinical trial during the past six (06) months. 15. Any other condition which the Investigator thinks may jeopardize the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in DAS-28 scoreTimepoint: 2.5 years | — |
Secondary
| Measure | Time frame |
|---|---|
| â?¢Change in Disability Index (The Indian Health Assessment Questionnaire) â?¢Change in acute phase reactants â?? ESR and CRP â?¢Change in Health Questionnaire SF-36 Timepoint: 2.5 years | — |
Countries
India
Contacts
Public ContactDR SHRIPRAKASH
National Veterinary Ayurveda Research institute and Hospital
Outcome results
None listed